Browsing Tag
Kailera Therapeutics
1 post
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.